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A B S T R A C T
Microbial production of plant specialised metabolites is challenging as the biosynthetic pathways are often
complex and can contain enzymes, which function is not supported in traditional production hosts.
Glucosinolates are specialised metabolites of strong commercial interest due to their health-promoting effects. In
this work, we engineered the production of benzyl glucosinolate in Escherichia coli. We systematically optimised
the production levels by first screening different expression strains and by modification of growth conditions and
media compositions. This resulted in production from undetectable to approximately 4.1 μM benzyl glucosi-
nolate, but also approximately 3.7 μM of desulfo-benzyl glucosinolate, the final intermediate of this pathway.
Additional optimisation of pathway flux through entry point cytochrome P450 enzymes and PAPS-dependent
sulfotransferase increased the production additionally 5-fold to 20.3 μM (equivalent to 8.3mg/L) benzyl glu-
cosinolate.
1. Introduction
A continuously increasing number of plant specialised metabolites are
considered high value compounds due to e.g. pharmaceutical, nutraceutical
or cosmetic properties. Production through natural sources is often not
sustainable because of low abundance of compound and/or source as well
as expensive purification processes (Ikram et al., 2015). The demand has
inspired researchers to apply metabolic engineering and synthetic biology
approaches to microorganisms. The efforts have led to innumerable reports
on heterologous production of plant specialised metabolites in expression
hosts such as Escherichia coli and Saccharomyces cerevisiae (Chae et al., 2017;
Cho et al., 2015; Huang et al., 2008; Pontrelli et al., 2018; Siddiqui et al.,
2012). Only few compounds have reached commercially relevant produc-
tion levels and production is most commonly reported in the μg/L to low
mg/L range (Chubukov et al., 2016; Pontrelli et al., 2018). In pursuit of still
higher titres, researchers continue to develop technologies in the fields of
omics, high-throughput analytics and computational engineering. Today,
strategies to increase yields often include multiple rounds of optimisation
and large mutant library screens - an approach also known as systems
metabolic engineering (Chae et al., 2017; Cho et al., 2015; Yang et al.,
2017). An emerging approach to identify bottlenecks and optimise flux
through a pathway is mass spectrometry-based targeted proteomics by se-
lected reaction monitoring (SRM). By using isotopically labelled synthetic
peptides as internal references in the samples, it is possible to determine not
only the presence but also the relative or absolute quantities of a given
protein of interest e.g. over time or at different conditions (Batth et al.,
2012). This method has been used successfully for increasing production
titres of several products in E. coli (Alonso-Gutierrez et al., 2015; Batth et al.,
2012; Brunk et al., 2016; Dahl et al., 2013; George et al., 2015, 2014;
Juminaga et al., 2012; Redding-Johanson et al., 2011; Singh et al., 2012;
Tan et al., 2016).
One group of plant specialised metabolites with commercial interest
is glucosinolates (GLSs). They are sulfur-rich compounds characteristic
of brassicaceous plants, including the model plant Arabidopsis thaliana
and several agriculturally important crops (Fahey et al., 2001). In
planta, GLSs constitute a line of defence, which becomes activated upon
attack from pathogens or herbivores (Jeschke and Burow, 2018). For
humans, the intake of brassicaceous vegetables has been associated
with reduced risks of cardiovascular diseases and several types of
cancer (reviewed in (Traka, 2016)), and with better insulin resistance
for type 2 diabetes (Bahadoran et al., 2012). These health beneficial
effects have made GLSs interesting as dietary supplements and primed a
desire to engineer microbial production as rich source of GLSs.
GLSs are derived from amino acids and synthesised through a core
structure pathway consisting of seven enzymatic steps (Fig. 1). Some
GLSs, e.g. the aliphatic methionine-derived GLSs, require chain
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elongation of the amino acid side chain before entering the core
structure pathway, and the side chains can be further modified as a final
step (Sønderby et al., 2010). Expression of multi-gene pathways in
microbial hosts can be difficult. The core GLS pathway is further
complicated by having two cytochrome P450 enzymes and two sulfur-
incorporating steps. The feasibility of engineering the GLS pathway in a
heterologous host was first shown by transient expression of the benzyl
GLS (BGLS) genes in Nicotiana benthamiana (Geu-Flores et al., 2009b).
This work identified an additional enzyme - a γ-glutamyl peptidase,
GGP1 - in the pathway (Geu-Flores et al., 2009a), and showed that the
reduced sulfur atom was derived from glutathione (Geu-Flores et al.,
2011). The final step of the pathway – the conversion of desulfo-BGLS
(dsBGLS) to BGLS - was identified as a metabolic bottleneck. This
conversion is catalysed by a sulfotransferase, which requires 3′-phos-
phoadenosine-5′-phosphosulfate (PAPS) as co-factor. The metabolic
bottleneck was alleviated by co-expressing the Arabidopsis kinase APK2
responsible for PAPS production (Møldrup et al., 2011). Having iden-
tified and overcome these basic metabolic bottlenecks in N. ben-
thamiana provided a basis for engineering of GLSs in microbial hosts.
The tryptophan-derived GLS indol-3-ylmethyl GLS (I3M) was produced
at 1.07mg/L in S. cerevisiae proving for the first time that GLSs can be
produced in a microbial organism (Mikkelsen et al., 2012). Recently,
two reports of engineering of GLS biosynthetic genes in E. coli have
been published. In 2016, the chain elongation pathway for methionine
was successfully expressed in E. coli resulting in the production of di-
homo-methionine, which is precursor to 4-methylsulfinylbutyl GLS
(4MSB) (Mirza et al., 2016). In 2018, 4MSB was produced in E. coli
although production levels were not quantified (Yang et al., 2018).
In this work, we set out to establish microbial production of the
phenylalanine-derived BGLS and systematically optimise the yields. E.
coli was chosen as production host, as previous reports showed it was
capable of expressing a GLS pathway despite its complexity (Yang et al.,
2018). The choice of expression strain, medium, cultivation conditions
and construct designs were all factors shown to have major effects on
BGLS yield in our production system. Targeted proteomics was used to
monitor the relative protein expression levels. We optimised production
levels to 20.3 μM (or 8.3mg/L) BGLS.
2. Materials and methods
2.1. Construct design and generation
The GLS biosynthetic gene sequences were found at www.
arabidopsis.org and codon optimised for E. coli expression using the
Codon Optimisation Tool from IDT (integrated DNA Technologies Inc,
USA http://eu.idtdna.com/CodonOpt). The optimised gene sequences
were ordered as gBlocks from IDT (Integrated DNA Technologies Inc,
USA) and cloned into expression vectors by Genewiz (New Jersey,
USA). The E. coli sulfate assimilation gene sequences cysC (adenylyl-
sulfate kinase), cysN (subunit of sulfate adenylyltransferase) and cysD
(subunit of sulfate adenylyltransferase) were found in UniprotKB da-
tabase and PCR amplified with Phusion® High Fidelity Polymerase (New
England Biolabs, USA) from genomic DNA of the BL21 (DE3) E. coli
strain (Table 1).
Fig. 1. Biosynthetic pathway of benzyl glucosinolate in Arabidopsis thaliana.
CYP79A2 and CYP83B1 are cytochrome P450s. GSTF9, GGP1, SUR1 and
UGT74B1 are a glutathione-S-transferaseF9, γ-glutamyl peptidase1, C-S lyase
and UDP-glucosyltransferase74B1. The SOT16 and SOT18 are sulfotransferases.
The pathway compounds are 1) phenylalanine, 2) phenylacetaldoxime, 3)
phenylacetonitrile oxide, 4) S-[(Z)-phenylacetohydroximoyl]-L-glutathione, 5)
Cys-Gly conjugate, 6) phenylacetothiohydroximic acid, 7) desulfo-benzyl glu-
cosinolate (dsBGLS) and 8) benzyl glucosinolate (BGLS).
Table 1
Engineered biosynthetic and support genes for BGLS production in E. coli. Gene names are listed with the type of enzyme, genomic locus in native host, length of gene
and percentage of nucleotide identity between wildtype and codon-optimised sequence.
Gene Type Locus Length Sequence identity Reference
CYP79A2 Cytochrome P450 At5g05260 1572 bp 74.9% Wittstock and Halkier (2000)
CYP83B1 Cytochrome P450 At4g31500 1500 bp 75.7% Naur et al. (2003)
GSTF9 Glutathione S-transferase At2g30860 648 bp 76.2% Mikkelsen et al. (2012)
GGP1 γ-glytamyl peptidase At4g30530 753 bp 74.8% Geu-Flores et al. (2009a)
SUR1 C-S lyase At2g20610 1389 bp 74.7% Mikkelsen et al. (2004)
UGT74B1 Glycosyltransferase At1g24100 1383 bp 74.8% Grubb et al. (2004)
SOT16 Sulfotransferase At1g74100 1017 bp 76.4% Piotrowski et al. (2004)
SOT18 Sulfotransferase At1g74090 1053 bp 76.5% Piotrowski et al. (2004)
ATR1 P450 reductase At4g24520 2079 bp 73.8% Mizutani and Ohta (1998)
cysC Adenylyl-sulfate kinase JW2720 606 bp 100% Satishchandran et al. (1992)
cysN Sulfate adenylyltransferase, subunit 1 JW2721 1428 bp 100% Leyh et al. (1988)
cysD Sulfate adenylyltransferase, subunit 2 JW2722 909 bp 100% Leyh et al. (1988)
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For this work pET-52b (Novagen®, Merck, #71554), pCDF-1b
(Novagen®, Merck, #71330) and pCOLADuetTM-1 (Novagen®, Merck,
#71406) were used as expression vectors. GGP1, SUR1 and ATR1 were
expressed from pCDF-1b (∼20–40 copies/cell). The remaining core
structure genes were expressed from pET-52b (∼40 copies/cell). The E.
coli sulfate assimilation pathway genes leading to PAPS, i.e. the two
subunits of sulfate adenylyltransferase (cysD and cysN) and the ade-
nylyl-sulfate kinase (cysC) were expressed from pCOLADuet (∼20–40
copies/cell). The construct is referred to as cysCND (Fig. 2C). All genes
were organised in separate operons using four different T7 promoters
with varying strengths: consensus, G6, H10 and C4 (naming as in (Jones
et al., 2015)). In the constructs indicated, the first eight residues of the
N-terminus anchors on the two P450 enzymes were exchanged with a
modified anchor of bovine CYP17A1 (hereafter bovine-modified) opti-
mised for E. coli expression (Barnes et al., 1991). DNA fragments en-
coding for the modified P450 anchor, the SOT18 enzyme as well as the
promoters for CYP79A2 and SOT enzymes were exchanged by ligation
cloning with T4 DNA ligase (Fig. 2 and Supplemental Fig. S1). The
sequences were ordered as gBlocks with appropriate restriction sites
(Integrated DNA Technologies Inc, USA) and ligated into the expression
vectors.
2.2. E. coli: strains, growth conditions and transformation
All cloning and plasmid amplifications were done in NEB® DH10B
strain (New England Biolabs, #C3019H). Cells were cultivated in Luria-
Bertani broth (LB Lennox, Duchefa, #L1703) containing 10 g tryptone,
5 g yeast extract and 5 g sodium chloride per litre, or Terrific Broth (TB)
containing 12 g tryptone, 24 g yeast extract, 5% glycerol (w/v), 0.17M
KH2PO4 and 0.72M K2HPO4 per litre. Transformations were performed
by heat-shock and the cells recovered in LB at 37 °C for 60min before
plating on LB agar plates with appropriate selection (50 μg/ml carbe-
nicillin, spectinomycin or kanamycin).
The constructs containing the core structure genes were trans-
formed into seven different expression strains (Table 2): four different
BL21 (DE3) strains inducible by isopropyl β-D-thiogalactopyranoside
(IPTG), as well as one BL21-AI strain and two cloning strains with the
T7 RNA polymerase expressed from a plasmid (pTARA, (Wycuff and
Matthews, 2000)) and inducible by arabinose. Five of the strains con-
tain an extra plasmid (pLysS, Rosetta, pRI952 or pTARA), which is
compatible with co-expression of the three expression plasmids (pET-
52b, pCDF-1b and pCOLA-duet).
For expression cultures, LB media was inoculated with single
Fig. 2. Design of multigene constructs for expression of BGLS pathway and support genes in E. coli. Promoters and ribosomal binding site sequences are represented
as grey arrows. Biosynthetic genes, terminator sequences and P450 bovine anchor are boxes coloured blue, red and yellow, respectively. A) The two constructs
containing the BGLS biosynthetic genes with choice of promoter indicated. B) For optimisation changes to the two constructs included bovine modification of N-
terminal anchor of P450 enzymes, change of promoters as well as use of different sulfotransferase genes. C) Construct used to overexpress the E. coli PAPS synthesis
pathway (adenylyl-sulfate kinase (cysC) and the two subunits of sulfate adenylyltransferase (cysD and cysN)), referred to as cysCND. D) T7 promoters used in this
study (Table modified from Jones et al. (2015)). Sequence differences are highlighted and the expression levels relative to the consensus T7 promoter are listed. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Table 2
Expression strains used for BGLS production. The strains are listed with the name used throughout this work and with strain specific characteristics.
Strain Name used Characteristics Reference
BL21 (DE3) BL21 (DE3) Genome integrated placUV5::T7 RNA polymerase NEB® C2527I
BL21 (DE3) pLysS pLysS BL21 (DE3) containing plasmid-expressed T7 lysozyme Promega L1191
Rosetta™ (DE3)pLysS Rosetta pLysS including rare tRNAs on plasmid Novagen®, Merck 70956
BL21 (DE3) with pRI952 pRI952 BL21 (DE3) with rare tRNAs on plasmid Del Tito et al. (1995)
One Shot® BL21-AITM BL21-AI Genome integrated paraBAD::T7 RNA polymerase ThermoFisher C6070-03
NEB® 5-alpha with pTARAa DH5a Cloning strain with plasmid-expressed paraBAD::T7 RNA polymerase NEB® C2987H
NEB® 10-beta with pTARAa DH10B Cloning strain with plasmid-expressed paraBAD::T7 RNA polymerase NEB® C3019H
a pTARA plasmid constructed in Wycuff and Matthews (2000).
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colonies and incubated over night at 37 °C, 200 rpm. The expression
cultures were cultivated in LB or TB as indicated and with the appro-
priate antibiotics (50 μg/mL carbenicillin, spectinomycin and/or ka-
namycin, 15 μg/ml chloramphenicol). Experiments were performed in
24-well plates with 4ml culture. Fresh media with appropriate selection
was inoculated to an OD600 of approximately 0.1 with the overnight
culture and allowed to grow at 37 °C and 200 rpm to an OD600 of ap-
proximately 0.6. At this point the cultures were induced with 0.5mM
IPTG or 0.1% (w/v) arabinose and grown at 18 °C and 120 rpm for 24 or
48 h before harvesting. Three individual colonies from each strain were
tested in triplicates for the metabolite analysis. When the cultures were
supplemented with various intermediates, the following concentrations
were added: 25 μM phenylacetaldoxime, 75mg/L 5-aminolevulinic
acid, 20 μM glutathione, 20 μM cysteine, 1mM thiamine or 20 μM
magnesium sulfate. When the strain overexpressing the cysCND con-
struct was supplemented with sulfur either 1mM cysteine and/or 50 μM
magnesium sulfate were used.
2.3. Metabolite extraction and LC-MS analysis
The supernatant was collected after centrifugation at 13,000×g for
5min. An aliquot of the supernatant was diluted 10-fold with milliQ
grade water and finally 1:10 (v/v) mixed with a stock solution con-
taining 10 μg/mL 13C-, 15N-labelled amino acids (Algal amino acids
13C, 15N, Isotec, Miamisburg, US) and 25 μM sinigrin (PhytoLab,
Vestenbergsgreuth, Germany). The resulting 100-fold diluted samples
were filtered (Durapore® 0.22 μm PVDF filters, Merck Millipore,
Tullagreen, Ireland) and used directly for LC-MS analysis.
The LC-MS analysis was performed as previously described (Mirza
et al., 2016) with changes as detailed below to monitor amino acid
levels simultaneously with products and intermediates of the BGLS
biosynthesis pathway. Briefly, chromatography was performed on an
Advance UHPLC system (Bruker, Bremen, Germany). Separation was
achieved on a Zorbax Eclipse XDB-C18 column (100×3.0mm, 1.8 μm,
Agilent Technologies, Germany). Formic acid (0.05% (v/v)) in water
and acetonitrile (supplied with 0.05% (v/v) formic acid) were em-
ployed as mobile phases A and B, respectively. The elution profile was:
0–1.2min 3% B; 1.2–4.3min 3–65% B; 4.3–4.4 min 65–100% B;
4.4–4.9 min 100% B, 4.9–5.0 min 100-3% B and 5.0–6.0min 3% B.
Mobile phase flow rate was 500 μl/min and column temperature was
maintained at 40 °C. The liquid chromatography was coupled to an
EVOQ Elite TripleQuad mass spectrometer (Bruker, Bremen, Germany)
equipped with an electrospray ionisation source (ESI). Instrument
parameters were optimised by infusion experiments with pure stan-
dards. The ionspray voltage was maintained at 3000 V or −4000 V in
positive or negative ionisation mode, respectively. Cone temperature
was set to 300 °C and cone gas flow to 20 psi. Heated probe temperature
was set to 400 °C and probe gas flow set to 50 psi. Nebulising gas was
set to 60 psi and collision gas to 1.6 mTorr. Nitrogen was used as both
cone gas and nebulising gas and argon as collision gas.
Multiple reaction monitoring (MRM) was used to monitor analyte
parent ion → product ion transitions: MRM for the 13C-, 15N-labelled
phenylalanine was chosen as previously described (Docimo et al.,
2012). MRMs for dsBGLS, BGLS and sinigrin were chosen as previously
described (Crocoll et al., 2016). Both Q1 and Q3 quadrupoles were
maintained at unit resolution. Bruker MS Workstation software (Ver-
sion 8.2.1, Bruker, Bremen, Germany) was used for data acquisition and
processing. BGLS and dsBGLS were quantified using sinigrin and 13C,
15N-Phe, respectively, as internal standards, except for Fig. 3A, where
quantification was performed based on a dilution series (linear re-
gression). Response factors were calculated based on dilution series of
the respective analytes. Internal standards were chosen based on
matching ionisation mode with the analyte of interest (i.e. negative
ionisation mode for glucosinolates and positive ionisation mode for
desulfo-glucosinolates and amino acids). Matrix effects from media and
cultivating E. coli were found to impair correct quantification of the
analytes. The correction factors for matrix effects have been calculated
into the response factors given in Supplemental Table S1. The presence
of the phenylacetaldoxime and the GSH-conjugated intermediate were
monitored without quantification. For analytes where multiple transi-
tions were monitored, the transition used for quantification is marked
as quantifier (Qt). Further details for transitions and collision energies
can be found in Supplemental Table S1. Visualisation and statistical
analysis were performed in RStudio v1.0.153 (R version 3.4.1) (RStudio
Team, 2015) using (Garnier, 2018; Wickham, 2016, 2011, 2007).
2.4. Targeted proteomics
2.4.1. Design of reference peptides
For each protein of interest, a set of proteotypic peptides was de-
signed and ordered as stable isotopically labelled synthetic peptides
(JPT, SpikeTides™). These were used as internal references in the
samples. Recently, a set of peptides covering most of the BGLS pathway
was designed and generously provided to us by Meike Burow and
Daniel Vik. We designed peptides for the remaining enzymes of the
pathway (ATR1 and GSTF9) and housekeeping enzymes from E. coli. A
list of peptides was obtained from each protein through an in silico
tryptic digest in Skyline 4.2 (MacLean et al., 2010). Suitable peptides
were selected based on the following criteria: 1) less than 1250m/z, 2)
no neighbouring arginine or lysine residue to the cleavage site, and 3)
avoidance of methionine and cysteine residues if possible. Each enzyme
was covered by a minimum of two non-neighbouring peptides
(Table 3).
2.4.2. Protein extraction and tryptic digest
Pellets from 1.5mL culture were harvested by centrifugation and
kept at −20 °C until extraction. Total protein extraction was performed
as previously described (Wessel and Flügge, 1984) with one exception:
centrifugation steps were done at 21,000×g for 1min at 4 °C. The
protein pellet was dried in Speed-Vac (30–60min, 1000 rpm, max
35 °C). The downstream protocol was modified from previously de-
scribed methods (Batth et al., 2012). The protein pellet was extracted
twice in 100 μl 100mM ammonium bicarbonate buffer with 10% (v/v)
methanol by sonicating for 2–5min in ultrasonic bath followed by a
Table 3
Proteotypic peptides of BGLS biosynthetic enzymes and an E. coli housekeeping
enzyme used for targeted proteomics analysis. Isotopically labelled synthetic
peptides were used as internal reference. Peptides marked with asterisk were
used for relative quantification.
Enzyme AGI code Peptide sequence Reference
CYP79A2 At5g05260 SWPLIGNLPEILGR This study
GNAFVVIDLR This study
LVIESDLPNLNYVK This study
LIQGFTWLPVPGK* This study
CYP83B1 At4g31500 GYVSEEDIPNLPYLK* This study
GQDFELLPFGSGR This study
LAVISSAELAK This study
GSTF9 At2g30860 LAGVLDVYEAHLSK* This study
GVAFETIPVDLMK This study
GGP1 At4g30530 DAITPGSYFGNEIPDSIAIIK* This study
VVSGEFPDEK This study
SUR1 At2g20610 FASIVPVLTLAGISK This study
IGWIALNDPEGVFETTK* This study
EENLVFLPGDALGLK This study
UGT74B1 At1g24100 GLPSLSYDELPSFVGR This study
SINEFIESLGK* This study
SOT16 At1g74100 VGDWANYLTPEMAAR This study
YDDAANPLLK* This study
SOT18 At1g74090 FDDSSNPLLK This study
VVNLCSFETLK* This study
ATR1 At4g24520 VIDLDDYAADDDQYEEK* This study
DEDDDLDLGSGK This study
ICD JW1122 GPLTTPVGGGIR Batth et al. (2014)
A. Petersen, et al. Metabolic Engineering 54 (2019) 24–34
27
brief centrifugation (1.5min at 1,000×g). Supernatant of both extrac-
tions was combined and protein concentration determined by Pierce™
BCA Protein Assay Kit (ThermoFisher, #23225). For tryptic digest,
100 μl of 0.5mg/ml protein extraction was used (50 μg total protein).
The extraction was incubated with 1 μl 10mM DTT for 30min at room
temperature. Subsequently, 25 μl 50mM iodoacetamide was added and
the samples incubated in the dark for 20min at room temperature. An
additional 100 μl 100mM ammonium bicarbonate buffer with 10% (v/
v) methanol was added with 1 μg trypsin/Lys-C mix (Promega,
#V5073) and the samples incubated over night at 37 °C. The digest was
stopped by adding 20 μl 10% (v/v) trifluoroacetic acid (TFA) and
samples were diluted up to 1.5 ml in buffer A (2% (v/v) acetonitrile and
0.1% (v/v) formic acid) and centrifuged (20,000×g for 15min). Pep-
tides were purified over Sep-Pak C-18 columns (Waters, Sep-Pak® Vac
1 cc 100mg, #WAT023590). Columns were attached to vacuum
manifold and equilibrated with 1ml buffer B (65% (v/v) acetonitrile
and 0.1% (v/v) formic acid) followed by 1ml buffer A. Next, the pep-
tide digest was loaded, followed by three washes with 1ml buffer A and
finally eluted with two times 0.5ml buffer B. Purified peptides were
dried by Speed-Vac (2–4 h, 1000 rpm, max 35 °C). Dried peptides were
kept at −20 °C until analysis. Just prior to LC-MS analysis, the dried
peptides were resuspended in 25 μl buffer C (2% (v/v) acetonitrile,
0.5% (v/v) formic acid and 0.1% (v/v) TFA), spiked with 20 nM iso-
topically labelled peptide standards (JPT, SpikeTides™), and filtered
through 0.22 μm centrifugal filters (#UFC30GV00, Merck, Darmstadt,
Germany).
2.4.3. LC-MS method
The gradient was adopted from Batth et al. (2014) and Percy et al.
(2012) with modifications. Briefly, formic acid (0.1% (v/v)) in water
and acetonitrile (supplied with 0.1% (v/v) formic acid) were employed
as mobile phases A and B, respectively. The elution profile was:
0–1.0min 5–10% B; 1.0–3.0min 10–11% B; 3.0–13.0 min 11–19% B;
13.0–21.0min 19–27.5% B, 21.0–21.7min 27.5–24% B; 21.7–22.5min
34–42% B; 22.5–23.5min 42–90% B, 23.5–26.9min 90% B,
26.9–30.0min 90-5% B and 30.0–34.0min 5% B. Mobile phase flow
rate was 500 μL/min and column temperature was maintained at 55 °C.
Peptide separation was achieved on an Aeris PEPTIDE, XB-C18 column
(1.7 μm, 2.1×150mm, Phenomenex, Palo Alto, USA) on an Advance
UHPLC-OLE (Bruker Daltonics, Bremen, Germany). The injection vo-
lume was 10 μL.
Source settings for heated electrospray ionisation were as follows:
spray voltage 3200 V, in positive ionisation mode; cone temperature
300 °C; cone gas flow 20 psi; heated probe temperature 300 °C; probe
gas flow 40 and nebuliser gas flow 50. Nitrogen was used as cone and
probe gas and argon as collision gas. The triple quadrupole mass
spectrometer (EVOQ Elite, Bruker Daltonics, Bremen, Germany) was set
to scan for parent ion → product ion transitions for individual peptides
within scheduled 3min windows. Resolution of the first and third
quadrupole was set to± 1Da. Detailed information on peptides in-
cluding retention times, transitions selected for detection and quanti-
fication and collision energies are summarised in Supplemental Table
S2. The acquired chromatograms were manually inspected and ratios
between endogenous light and synthetic heavy peptides were obtained
through Skyline 4.2 for each peptide (MacLean et al., 2010). Relative
quantification was performed by normalisation to heavy peptides, fol-
lowed by normalisation to the housekeeping protein ICD and plotted
relative to the CSaro control. Undetected peptides (N/A) were treated
as zero values for analysis. Additional statistical analyses and visuali-
sation were performed in RStudio v1.0.153 (R version 3.4.1) (RStudio
Team, 2015) using (de Mendiburu, 2017; Wickham, 2016, 2011, 2007).
3. Results
3.1. Establishment of dsBGLS production in E. coli
The biosynthetic pathway of phenylalanine-derived BGLS consisting
of seven genes - CYP79A2, CYP83B1, GSTF9, GGP1, SUR1, UGT74B1
and SOT16 - was chosen for engineering and optimising GLS production
in E. coli. The NADPH cytochrome P450 reductase, ATR1, from A.
thaliana was included, as E. coli does not efficiently support the function
of cytochrome P450 enzymes (Park et al., 2013). The pathway was
expressed from plasmids to enable efficient and rapid modifications of
the construct design. The genes were divided between two medium to
high copy-number plasmids and all genes were expressed from IPTG- or
arabinose-inducible T7 promoters (Fig. 2A). Different T7 promoters
were used as a previous study showed that choice of T7 promoters can
affect production levels substantially (Jones et al., 2015). Based on
previous findings on the evolutionarily related cyanogenic glucoside
biosynthetic pathway (Laursen et al., 2016) and on the low frequency
by which CYP79s compared to CYP83s are found in classical shotgun
proteomics approaches in Arabidopsis, we expected CYP83s to be pre-
sent in higher levels than CYP79s in planta (Baerenfaller et al., 2011;
Laursen et al., 2016). We therefore chose to express CYP83B1 from a
consensus T7 promoter and the other genes from the weaker G6 pro-
moter.
First, the widely used BL21 (DE3) expression strain was engineered
with the BGLS pathway. Besides the desired product BGLS, three in-
termediates of the pathway were monitored: phenylacetaldoxime, the
GSH conjugate and dsBGLS (Fig. 1). No product was detected when
expression was performed at 28 °C. Upon lowering the temperature to
18 °C, dsBGLS was produced, but still none of the other monitored
products were detected (data not shown). As dsBGLS is the final in-
termediate of the pathway (Fig. 1), this result indicated functionality of
all but the ultimate sulfotransferase step. The OD600 at the time of in-
duction proved important to titres with optimal production after an
induction at OD600≈ 0.6 (data not shown). Harvesting 48 h after in-
duction resulted in 4.74 μM dsBGLS, but still no BGLS was detected.
Based on these results, subsequent experiments were performed by in-
ducing expression at OD600≈ 0.6 and allowing production cultures to
grow at 18 °C for 48 h after induction.
3.2. Screening of different E. coli strains for production
The plasmids containing the BGLS genes were transformed into six
additional E. coli strains to investigate whether strain specificity would
result in BGLS production. The BL21 (DE3) strain was included as
control. Strains pRI952 and Rosetta are engineered with rare tRNAs to
help expression. BL21-AI has the T7 RNA polymerase expressed from
the araBAD promoter enabling repression of potential toxic, leaky ex-
pression by glucose (Miyada et al., 1984). The pLysS strain represses
expression until IPTG induction through the T7 lysozyme (Studier,
1991). These five strains are all of the classical B-lineage of E. coli. Two
K-12-derived strains, DH5a and DH10B, were included as an alter-
native. These were transformed with the pTARA plasmid carrying the
T7 RNA polymerase expressed from the araBAD promoter like the BL21-
AI strain (Wycuff and Matthews, 2000).
When seven different E. coli strains harbouring the BGLS biosyn-
thetic genes were grown for 48 h at 18 °C, differences in dsBGLS pro-
duction were observed (Fig. 3A). The highest-producing strains were
the standard strain BL21 (DE3) and the pRI952. The latter produced
1.6-fold more dsBGLS than BL21 (DE3). These two strains were selected
for further optimisations.
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3.3. Optimisation of medium composition
3.3.1. Supplying additives or intermediates of the pathway
The first two enzymes of the BGLS pathway are the heme-containing
P450 proteins. Supplementation of medium with heme precursor 5-
aminolevulinic acid was previously shown to improve activity of P450
enzymes in E. coli (Hansen et al., 2001; Pritchard et al., 1997; Wittstock
and Halkier, 2000). When the expression cultures were fed with 5-
aminolevulinic acid to investigate whether co-factor supplement would
result in BGLS production only little increase in dsBGLS levels and still
no BGLS was observed (Fig. 3B). When feeding the first intermediate of
the BGLS pathway, phenylacetaldoxime, production of dsBGLS was
increased 10-fold and 7-fold in strains BL21 (DE3) and pRI952, re-
spectively. This indicated that the entry point to the pathway was a
metabolic bottleneck.
The BGLS pathway contains two sulfur-incorporating enzymatic
steps; the glutathione-conjugation reaction by GSTF9 and the transfer
of sulfate by SOT16 (Fig. 1). When the cultures were supplemented with
glutathione, no effect on production levels was observed suggesting that
glutathione is not limiting (Fig. 3B). The second sulfur-incorporation
step is responsible for the conversion of dsBGLS to BGLS, and hence the
step of the pathway, which appeared non-functional. Sulfotransferase
(SOT) enzymes transfer a sulfate moiety from PAPS onto dsGLSs (Klein
and Papenbrock, 2009). PAPS is a product of the sulfate assimilation
pathway (Kopriva and Koprivova, 2004). To increase the SOT activity
and obtain BGLS, different sulfur sources were fed to the expression
cultures in the form of cysteine, thiamine and magnesium sulfate. This
did not result in any BGLS production, and both cysteine and thiamine
appeared to hamper production of dsBGLS (Fig. 3B). The pRI952 strain
proved consistently better than the BL21 (DE3) and subsequent ex-
periments were carried out using only this strain.
3.3.2. Production of BGLS using TB medium
Instead of supplementing individual compounds to the medium, the
LB medium was exchanged with the more nutritious TB medium that
predominantly differs by containing approximately 5-fold more yeast
extract and by being buffered by potassium phosphate (KPi). BGLS was
produced in TB to levels of approximately 4.1 μM (Fig. 4A). This is
comparable to the production of I3M in S. cerevisiae (2.38 μM,
Mikkelsen et al., 2012). Only dsBGLS was detected in LB medium.
When KPi buffer was added to LB medium to investigate if the
phosphate buffer and thus the control of pH was the determining factor
for dsBGLS to BGLS conversion in TB medium, still only dsBGLS was
produced. This suggests that component(s) in the yeast extract are
critical for SOT activity (Fig. 4A).
3.4. Towards elimination of metabolic bottlenecks
3.4.1. Overexpression of E. coli PAPS-producing genes
Approximately one third of the produced dsBGLS is converted to the
desired product, BGLS, when cultivating the pRI952 strain in TB
medium. As mentioned above, the sulfotransferase responsible for this
conversion needs PAPS as a co-factor. In E. coli, the genes responsible
for producing PAPS in the sulfate assimilatory pathway are cysC en-
coding for an adenylyl-sulfate kinase and cysN and cysD encoding for
two subunits of a sulfate adenylyltransferase (Kopriva and Koprivova,
2004). To increase the levels of available PAPS, a construct harbouring
these genes driven by different T7 promoters was generated (Fig. 2C,
construct cysCND). When cultures of pRI952 strain expressing the BGLS
pathway genes and overexpressing cysCND were supplemented with
Fig. 3. Production level of dsBGLS in LB medium of E. coli expressing the BGLS biosynthetic genes. A) Seven different E. coli strains were grown for 48 h at 18 °C and
the media were analysed for GLS production. B) The BL21 (DE3) and pRI952 strains were grown in media supplemented with either 25 μM phenylacetaldoxime,
75mg/L 5-aminolevulinic acid or different sulfur sources (20 μM glutathione, 20 μM cysteine, 1 mM thiamine or 20 μM magnesium sulfate). Data represent the
average and standard deviation of three biological replicates each grown in three technical replicates.
Fig. 4. Medium levels of dsBGLS and BGLS produced by pRI952 E. coli strain
grown in different media and with sulfur supplements. A) Production of dsBGLS
and BGLS in medium by the pRI952 strain grown in LB, LB with KPi buffer or TB
medium. B) as A) except the TB medium is supplemented with different sulfur
sources. C) as B) except the strain harbours the cysCND construct in addition to
the BGLS biosynthesis genes. Data represent the average and standard deviation
of three biological replicates each grown in three technical replicates.
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magnesium sulfate or cysteine or both as sulfur sources, no increase in
the BGLS levels was observed, on the contrary BGLS levels were re-
duced (Fig. 4B and C). Similarly, in the strain expressing only the BGLS
pathway genes and fed with added cysteine, BGLS levels were also re-
duced, showing that BGLS production is reduced when cysteine is
supplemented, despite overexpression of the PAPS producing genes.
However, supplementing with cysteine more than doubled the pro-
duction of dsBGLS by the wildtype strain compared to the cysCND-
overexpressing strain (Fig. 4B and C). This could possibly be explained
by higher levels of glutathione as a result of endogenous regulation to
establish cellular equilibrium. This regulation may have been disrupted
in strains expressing the cysCND construct, which could explain the
lack of increased dsBGLS production (Fig. 4C).
3.4.2. Effect of choice of promoters and P450 N-terminal anchors
The increase in dsBGLS upon feeding with the first intermediate of
the pathway, phenylacetaldoxime, shows that the CYP79A2 activity is
limiting (Fig. 3B), and the general accumulation of dsBGLS rather than
BGLS shows that the SOT activity is limiting (Figs. 4 and 5). A series of
new constructs were designed as an alternative approach to increase
P450 and SOT activity (Fig. 2B). As a means to increase P450 enzyme
activity, the anchors on both P450 enzymes were replaced with an N-
terminal sequence of the bovine CYP17A1 (Optimisation strategy
(hereafter Opt) 1) ((Barnes et al., 1991). This approach has previously
been used successfully to increase the expression of cytochrome P450
enzymes in E. coli (Barnes et al., 1991; Goder and Spiess, 2003; Ichinose
and Wariishi, 2013), including CYP79A2 (Wittstock and Halkier, 2000).
To increase expression of specifically CYP79A2, this gene was placed in
front of a consensus T7 promoter (Opt 2), which is stronger than the
replaced G6 (Fig. 2D). A similar approach was employed for the SOT16
gene, which was driven by the H10 promoter (Opt 3). These three
optimisation strategies were combined into, respectively, Opt 4 (Opt
1+2) and Opt 5 (Opt 1+2+3). Additionally, two constructs were
made to optimise the conversion of dsBGLS to BGLS. A. thaliana con-
tains three SOT enzymes (SOT16-18) affiliated with the GLS pathways
(Piotrowski et al., 2004). SOT16 and SOT18 have been shown to con-
vert dsBGLS to BGLS equally well (Møldrup et al., 2011). To test if
SOT18 will perform better in E. coli, we replaced SOT16 with SOT18
expressed from both the H10 promoter (Opt 6) and from the stronger
C4 promoter (Opt 7).
The highest production levels of dsBGLS and BGLS were seen in
strains harbouring a construct containing the following changes: bo-
vine-modified anchors on both CYPs, stronger promoter (consensus T7)
for CYP79A2 and stronger promoter (H10) for SOT16 (Opt 5). This
combination increased production of dsBGLS and BGLS by 3.7- and 5-
fold, respectively, compared to the unmodified construct. Production in
the Opt 4 (bovine-modified P450 anchors and stronger promoter for
CYP79A2) was similar to Opt 5, however the conversion of dsBGLS to
BGLS was significantly improved in Opt 5, resulting in higher BGLS
production when compared to Opt 4. The increased production in Opt 4
and Opt 5, which both have the bovine-modified P450 anchors and a
stronger promoter driving CYP79A2, when compared to the remaining
constructs indicates that CYP79A2 was a bottleneck in the pathway.
This limitation was improved by protein engineering and increased
promoter strength for the gene.
The other bottleneck resulting in dsBGLS accumulation and thus
involving the SOT enzyme was addressed with a similar strategy.
Increasing the strength of the promoter driving SOT16 expression (Opt
3) did improve the conversion of dsBGLS to BGLS when compared to
the unmodified construct. In strains expressing SOT18 from the H10
(Opt 6), the conversion of dsBGLS to BGLS is significantly improved
compared to the unmodified construct, but not compared to Opt 3. The
construct with highest SOT18 expression (Opt 7) also resulted in the
most favourable dsBGLS/BGLS ratio (Fig. 5).
3.4.3. Protein expression levels of BGLS biosynthetic enzymes after
optimisation
A targeted proteomics approach was applied to monitor effects of
the different optimisation strategies on the protein expression levels.
For all proteins, the level was determined from a minimum of two
peptides, with the exception of GGP1 for which only one peptide was
quantifiable (Fig. 6 and Supplemental Fig. S2). Higher levels of
CYP79A2 but not CYP83B1 were detected when the N-terminal anchors
were bovine-modified (Fig. 6B and C, Opt 1, 4 & 5), but not when the
stronger consensus T7 promoter was used for CYP79A2 (Fig. 6B, Opt 2).
When the SOT16 and SOT18 were expressed from H10 and C4 pro-
moters, it resulted in increased SOT levels when compared to expres-
sion from the G6 promoter (Fig. 6H and I, Opt 3, 6 and 7). GGP1, SUR1
and ATR1 showed similar protein levels in all samples (Fig. 6A, E & F).
Unexpectedly, modifying the anchors on the two P450 enzymes re-
sulted in increased GSTF9 levels, which is unchanged at all other con-
ditions (Fig. 6D, Opt 1, 4, & 5).
4. Discussion
In this work, we report the first production of BGLS in a microbial
host and the first quantified GLS production in E. coli. We found that
growing the cultures at 18 °C rather than 28 °C and having a cell density
of OD600 at 0.6 at the time of induction was crucial to obtain produc-
tion. These factors are known to influence production from hetero-
logous pathways and can vary greatly for different compounds
(Galloway et al., 2003; Huyen et al., 2015; San-Miguel et al., 2013;
Sørensen and Mortensen, 2005). Previous reports have shown that ex-
pression temperatures below 20 °C improved production of
Fig. 5. Production of dsBGLS and BGLS in medium
from pRI952 E. coli strain upon optimisation of CYP
and SOT activity. The two P450 enzymes were N-
terminally bovine-modified and CYP79A2 expressed
from a stronger T7 promoter. Both SOT16 and SOT18
were tested driven from different T7 promoters.
Table indicates the changes made to the original
constructs containing the BGLS biosynthetic genes
(CSaro). Data represent the average and standard
deviation of three biological replicates each grown in
three technical replicates. Pairwise t-tests were per-
formed on the dataset. Results can be found in
Supplemental Tables 3–5.
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phenylacetaldoxime by CYP79A2 (Miki and Asano, 2014), which cor-
responds well with our results. Additionally, harvesting after 48 h
compared to 24 h as well as choosing the pRI952 strain compared to a
standard BL21 (DE3) (Fig. 3A) improved our production 21.5- and 1.6-
fold, respectively. The most crucial optimisation for BGLS production
was changing to a more nutritious medium composition. In standard LB
medium only dsBGLS was produced but upon cultivation of the E. coli
strains harbouring the BGLS biosynthetic pathway in TB medium, ap-
proximately one third of the dsBGLS was converted to BGLS (Fig. 4A).
Both, dsBGLS and BGLS were detected in the medium without first
disrupting the cells. This corresponds well to previously published mi-
crobial GLS engineering studies, which all found the products extra-
cellularly (Mikkelsen et al., 2012; Mirza et al., 2016; Yang et al., 2018).
Metabolic bottlenecks identified in this study are associated with
the P450 and SOT enzymes. This is based on an increased production
when feeding the CYP79A2 product (phenylacetaldoxime) and opti-
mising the CYP79A2 enzyme expression, as well as improved dsBGLS/
BGLS ratio when optimising the SOT enzymes expression. Many studies
have focused on optimising activity of eukaryotic P450 enzymes in E.
coli. Being membrane-associated proteins, overexpression can cause
severe growth inhibition and influence the energy metabolism of E. coli
(Wagner et al., 2007). Particularly, plant P450 enzymes can have pro-
blems with proper folding, membrane translocation and toxicity to the
host cell (Chemler and Koffas, 2008). In this work, the BGLS-producing
E. coli strains were not affected in growth compared to strains with
empty vector control, and both CYP79A2 and CYP83B1 - representing
the entry point to the engineered pathway - were functionally ex-
pressed. When the N-terminals on CYP79A2 and CYP83B1 were mod-
ified with the bovine anchor known to improve P450 expression in E.
coli (Barnes et al., 1991; Goder and Spiess, 2003; Ichinose and Wariishi,
2013; Miki and Asano, 2014), protein levels of CYP79A2, but not
CYP83B1, increased (Fig. 6B and C) along with the production of both
dsBGLS and BGLS (Fig. 5), reflecting increased flux through the
pathway. This modification also increased levels of GSTF9 (Fig. 6D)
that is expressed just downstream of CYP79A2 in the construct. This
apparent linked co-expression between CYP79A2 and GSTF9 could be
explained by an increased transcription of CYP79A2, which mistakenly
continues as a read-through to the neighbouring GSTF9. This is, how-
ever, unlikely as the nucleotide sequences are identical apart from the
modified CYP anchor and the increased protein levels of GSTF9 might
be the result of unknown cellular regulatory mechanisms.
For the metabolic bottleneck associated with the final PAPS-de-
pendent sulfotransferase step converting dsBGLS to BGLS, even the
best-producing strain converted little more than half of the dsBGLS to
BGLS. As the conversion requires incorporation of sulfate, BGLS pro-
duction likely affects sulfur metabolism of the host. In N. benthamiana,
the same step was identified as a metabolic bottleneck in BGLS pro-
duction, but could be alleviated by co-expressing an Arabidopsis PAPS
kinase, APK2 (Møldrup et al., 2011). Overexpression of E. coli adenylyl-
sulfate kinase (cysC) and sulfate adenylyltransferase (cysND) designed
to increase the PAPS pool, did not improve conversion of dsBGLS to
BGLS (Fig. 4C). In fact, overexpression of these genes appears to be a
disadvantage when the cultures are supplemented with additional cy-
steine. Although BGLS levels were reduced at any level of cysCND ex-
pression when cysteine is supplemented, dsBGLS was produced in ap-
proximately twice as high amounts in wildtype strains compared to
cysCND-overexpressor strains (Fig. 4B and C). In the former, the addi-
tional cysteine may increase the availability of glutathione that is re-
quired for the earlier sulfur-incorporating step leading to the thio-glu-
cose moiety in the GLS structure. In the cysCND-overexpressor strain
regulation of the entire sulfate assimilation pathway may be compro-
mised as most of the pathway is regulated at a transcriptional level
(Rossi et al., 2014). This in turn might hamper the cells ability to
channel the additional sulfur efficiently towards glutathione and thus
dsBGLS production.
Uptake of sulfur from the environment is tightly regulated and de-
pendent on available as well as preferred sources (Guédon and Martin-
Verstraete, 2007). For E. coli, the main sulfur source from the en-
vironment is sulfate, while cysteine if present is the preferred source
(Kredich, 2008). Sufficient cysteine in the environment represses ex-
pression of the sulfate assimilation pathway. This could well explain the
complete loss of BGLS when cysteine was feed to the expression
Fig. 6. Protein levels in pRI952 E. coli strain upon optimisation of CYP and SOT activity. Targeted proteomics was used to monitor the protein level of enzymes in
BGLS biosynthesis. A representative peptide for each protein is shown. Data represent the average and standard deviation of protein level in three biological
replicates normalised to a housekeeping protein and relative to expression seen from the original, unmodified constructs (CSaro). Letters denote significant dif-
ferences between samples (P < 0.05 Tukey HSD test).
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cultures, as available PAPS would decrease or vanish. Conversely, when
cysteine is scarce, expression of the assimilation pathway as well as
import of sulfate are increased (Kredich, 2008; Rossi et al., 2014). In the
assimilation pathway, both PAPS and its precursor APS (adenosine 5′-
phosphosulfate) are signalling molecules. APS signals sufficient in-
organic sulfate source and will thus promote the assimilation pathway
(Guédon and Martin-Verstraete, 2007). PAPS has broader signalling
effects, which are not fully elucidated, but it has been shown to affect
global gene transcription through inhibition of nucleotide diphosphate
kinase (Ndk) (Rossi et al., 2014). Thus, if overexpression of cysCND
leads to accumulation of PAPS, this could negatively affect expression
of the BGLS pathway genes.
The most promising result with regards to dsBGLS to BGLS con-
version was seen in cultures with higher SOT expression. Increasing the
SOT enzyme levels by expressing the gene from the strong C4 promoter
improved the BGLS/dsBGLS ratio significantly when compared to any
other construct. This suggests that the E. coli cells contain a PAPS pool,
which the SOT enzymes cannot access and/or utilise efficiently.
5. Conclusion
Optimisation strategies included test of different expression strains,
cultivation conditions and media compositions, as well as modification
of flux through the exogenous BGLS pathway and the endogenous sulfur
metabolism. A targeted proteomics approach uncovered how changes
in genetic regulatory elements affected levels of the BGLS biosynthetic
enzymes and showed that increasing promoter strength did not ne-
cessarily yield higher protein levels, but could in fact result in decreased
levels. Similarly, modifying N-terminal anchors on the P450 enzymes
according to previously reported bovine modification had different ef-
fects depending on the enzyme in question. Interestingly, increased
CYP79A2 levels caused several folds increase in the neighbouring
GSTF9. Generally, the modifications to the P450 and SOT genes, which
are co-located on the pET-52b plasmid, appear to affect the expression
levels of other genes expressed from that plasmid. In contrast, genes
(GGP1, SUR1, and ATR1) expressed from the pCDF-1b plasmid did not
alter protein levels under the different optimisation approaches, with
the exception of ATR1 in Opt 5, which is mildly reduced.
The metabolic bottlenecks identified through our work were related
to the expression of the two cytochrome P450s and the two sulfur-in-
corporating steps. The P450 expression was improved by increasing
promoter strength for the genes. For the sulfur incorporation, solutions
that previously alleviated the same bottleneck in N. benthamiana, did
not translate into the microbial host system. Feeding sulfur sources
increased dsBGLS production but at the cost of BGLS. This increased
dsBGLS production indicates that both sulfur-incorporating steps are
limiting for the flux through the pathway. Increased expression of the
SOT18 protein improved the ratio of dsBGLS/BGLS. However, no con-
dition or strain tested enabled complete conversion of dsBGLS to BGLS.
In summary, our work identified and addressed metabolic bottlenecks
and optimised the production to 20.3 μM BGLS accompanied by
13.5 μM dsBGLS.
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